03:45 PM EST - Aeterna Zentaris Inc. : Announced it has successfully completed patient recruitment for the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) as a growth hormone stimulation test for the evaluation of growth hormone deficiency in adults. Aeterna Zentaris Inc.
shares T.AEZ are trading down $0.52 at $5.59.
